MedTrace Logo

Clinical Study to Evaluate the Efficacy and Safety of Matrix Pro Treatment

NCT06726122 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-15

No results posted yet for this study

Summary

This is a non-randomized, multi-center, open-label, prospective clinical trial evaluating clinical treatments with the Matrix Pro Applicator for the improvement of facial and/or submental and neck laxity.

Conditions

  • Skin Laxity
  • Wrinkle
  • Skin Condition

Interventions

DEVICE

Profound Matrix

Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).

Sponsors & Collaborators

  • Candela Corporation

    lead INDUSTRY

Principal Investigators

  • Konika Schallen, MD · Candela Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-28
Primary Completion
2028-01-31
Completion
2028-05-31
FDA Device
Yes

Countries

  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06726122 on ClinicalTrials.gov